Finally got to the CC from the last quarter (iced in today) and thought the information was high quality, as usual. I clearly got a little ahead of myself with the past post about the CVD partnership and now am better informed about the rollout there. Looks to me that '14 guidance does not anticipate ANY of that potential revenue, so the upside is considerable. Liked what I heard in discussions about M&A.
Good, but not nearly a blowout. The co. has absorbed (or is planning to absorb) the rest of the medicare reimbursement cuts well enough to have this become a non-issue and they are clearly managing the co. well, but there has been little, if any, impact yet from the CVD deal and I would have expected some more in the PR about the deal other than the generic statement. I'll wait for the CC to reserve judgment, but was hoping for 1-2C/share better than we got. We will still be small potatoes until we get past $25 million/quarter and that's still pretty small potatoes.
Looks like the answer is ABT has reduced its stake down to the 800K shares. At the bottom of the filing, NEO checked the box that ABT is no longer a beneficial owner of at least 5% of the co. If indeed ABT was tied to NEO because of the potential for MelanoSite, then one could surmise that MelanoSite did not pan out. ABT still made some good money on their investment.
Bill, that you? I stumbled across this on a cross post. My NEO in this sector is doing great! The fundamentals on PABC look good and the sector is going to become red hot. Got more DD to do, but I like what I see. Long time since CAMH days, but with that kind of loss, I need to keep plugging away.
hgrvy, this has been a rather tight board community. We'll definitely see the influx of bashers/pumpers as our profile rises. Anyone ever hear from retiredtechie, he's the one who put me onto NEO.
YAGS, thanks for the heads-up on INO, I will give it a look and run down some opinions about it, see what I can find. Tips like this could be gold; I got the NEO tip from a chat room as well as my biggest gold play, MUX (which used to be MNEAF). Davidy, I also like NXTM, they are growing, have the ONLY in-home dialysis machine that is medicare reimbursable and good portable dialysis products. They had disappointed the last quarter (the first fully independent EU distribution Q for them), but just guided up 2 days ago and the numbers look good.
Let's please try to remain civil here, most YMB's suck and we've avoided that here. Yags has been around for a long time and I respect his/her skepticism, even though I disagree with it. Clearly, a new base is forming and I am still looking at my investment here in a frame of 24-36 months out (as I have always done; I still find few investments that are more attractive) and have been pleased with my return, going back to 2007. So, let's be respectful and have substantive debate about NEO, please.
well, you are correct in that the risk for us has to do with medicare reimbursement, but it is a much smaller risk than the potential for the CVD deal. I suggest you re-read the CVD PR including the following, "Douglas VanOort, NeoGenomics Chairman and CEO, stated, "Our oncology-focused genetic and molecular testing services are a perfect complement to Covance's extensive laboratory services and will allow NeoGenomics to rapidly grow its clinical trials business with a world-class partner. We also look forward to the exciting opportunities that this collaboration will open up in the field of companion diagnostics."
As I see it, CVD is inviting us in to their extensive lab facilities worldwide, providing us with work, and allowing us to utilize these facilities to provide clinical diagnostic services worldwide. The upside potential here is HUGE!
Measuring Jak2 status for myeloproliferative disorders (including CML's) appears to be an important piece of information with regard to the specific treatment regimen. The combined number of different leukemias is considerable with regard to prevalence, so the test should be in demand. That said, there is no guarantee that we will see a big uptick in adoption as history dictates that medicare reimbursement code allowance is the BIG hurdle in making tests like this a standard.
Can't find anything on William Blair, but this is certainly a robust move up. Blew through $4 with ease, now let's see about an all-time high!
I have seen this go wrong before, but the price action today for NEO and several other healthcare stocks in my portfolio had a nice boost today, suggesting that the reimbursement issue may be settling. The atmosphere for fixing reimbursement for part B services has been positive, with word the SGR will finally be sunsetted and a permanent fix made to replace this. I am willing to bet that this will include something other than the draconian cuts to lab services as well. Hoping that something happened on the hill yesterday that confirmed this and that's why these co.'s went dramatically up. If we are clear, we have something very special to look forward to here with NEO.
I haven't posted for a long time but have held steady with my investment here. The co. has such a long history of missteps that none of the recent good news is convincing to me and apparently to investors in general. That said, the recent news (revenue, drug outcomes and NDA) will eventually lead to a more consistent and increasing revenue stream. Oncologists don't ignore ASCO findings. The co. will simply have to show the street "the money" to convince all that it is worth more.